

Cheap Nursing CEUs

HIV in Prison Populations

1. Which of the following statements is most accurate?

- A. HIV-2 is associated with higher viral load levels, slower rates of CD4 decline, and slower rates of clinical progression, as compared with HIV-1.
 - B. HIV-2 is associated with higher viral load levels, faster rates of CD4 decline, and faster rates of clinical progression, as compared with HIV-1.
 - C. " HIV-2 is associated with lower viral load levels, faster rates of CD4 decline, and faster rates of clinical progression, as compared with HIV-1. "
 - D. HIV-2 is associated with lower viral load levels, slower rates of CD4 decline, and slower rates of clinical progression, as compared with HIV-1.
-

2. Which of the following statements is most accurate?

- A. HIV-infected women, 21 – 29 years old, should have a baseline Pap test at the time of initial diagnosis with HIV.
 - B. HIV-infected women, 21–29 years old, should not have a baseline Pap test at the time of initial diagnosis with HIV.
 - C. HIV-infected women, 30–35 years old, should have a baseline Pap test at the time of initial diagnosis with HIV.
 - D. HIV-infected women, 36–42 years old, should have a baseline Pap test at the time of initial diagnosis with HIV.
-

3. Inactivated vaccines are generally not safe or acceptable in HIV-infected individuals.

- A. True
 - B. False
-

4. The preferred treatment regimen for latent tuberculosis infections in HIV-positive patients is most likely to include which of the following doses of Isoniazid?

- A. Isoniazid 300 mg daily
 - B. Isoniazid 300 mg twice daily
 - C. Isoniazid 300 mg weekly
 - D. Isoniazid 600 mg twice weekly
-

5. Deferring ART until CD4 counts decline puts individuals at risk of AIDS-defining conditions and has been associated with higher risk of morbidity and mortality.

- A. True

B. False

6. Which of the following statements is most accurate?

- A. Avoid the use of abacavir-containing NRTI backbone combinations in chronic hepatitis C co-infected patients unless combined with effective hepatitis antiviral therapy.
 - B. Avoid the use of abacavir-containing NRTI backbone combinations in chronic hepatitis C co-infected patients over the age of 35.
 - C. Avoid the use of abacavir-containing NRTI backbone combinations in chronic hepatitis B co-infected patients unless combined with effective hepatitis antiviral therapy.
 - D. Avoid use of abacavir-containing NRTI backbone combinations in chronic hepatitis B co-infected patients over the age of 65.
-

7. Which of the following statements is most accurate?

- A. Raltegravir can be given as 400 mg once daily, or 1200 mg once weekly.
 - B. Raltegravir can be given as 400 mg twice daily, or 1600 mg once daily.
 - C. Raltegravir can be given as 400 mg three times a day, or 1600 mg once daily.
 - D. Raltegravir can be given as 400 mg twice daily, or 1200 mg once daily.
-

8. Which of the following statements is most accurate?

- A. Truvada requires renal dosing in patient population with CrCL ≥ 20 ml/min.
 - B. Truvada requires renal dosing in patient population with CrCL ≥ 30 ml/min.
 - C. Truvada requires renal dosing in patient population with CrCL ≥ 50 ml/min.
 - D. Truvada does not require renal dosing.
-

9. A boosted PI-based regimen may be preferred for patients who are at high risk for intermittent therapy.

- A. True
 - B. False
-

10. Which of the following adverse effect is most likely to be associated with efavirenz?

- A. QTc prolongation
 - B. Spontaneous bleeding
 - C. "Bone marrow suppression"
 - D. Cardiovascular disease
-

11. A 32-year-old male patient has recently been initiated on zidovudine. The patient has questions about zidovudine. Which of the following counseling points should be expressed to the patient regarding zidovudine therapy?

- A. Zidovudine may cause gastrointestinal effects.
 - B. Zidovudine may only causes gastrointestinal effects in patients over the age of 35.
 - C. Zidovudine does not typically cause gastrointestinal effects.
 - D. Discontinue therapy 24 hours after experiencing side effects.
-

12. "Virologic failure is the inability to achieve or maintain suppression of viral replication to an HIV RNA level<200 copies."

- A. True
 - B. False
-

13. A 28-year-old male patient has recently been initiated on ART. The patient has questions about his ART. Which of the following counseling points should be expressed to the patient regarding ART?

- A. Discontinue therapy 24 hours after experiencing side effects.
 - B. Discontinue therapy 48 hours after experiencing side effects.
 - C. Discontinuing ART does not typically affect viral load.
 - D. "Discontinuing ART may result in viral rebound, immune decompensation, and clinical progression. "
-

14. Which of the following statements regarding pneumocystis pneumonia prophylaxis is most accurate?

- A. Prophylaxis should begin in HIV-infected patients with a CD4 count <200 cells/?L.
 - B. Prophylaxis should begin in HIV-infected patients with a CD4 count <400 cells/?L.
 - C. Prophylaxis should begin in HIV-infected patients with a CD4 count <600 cells/?L.
 - D. Prophylaxis should begin in HIV-infected patients with a CD4 count <800 cells/?L.
-

15. The first medication choice for toxoplasmosis prophylaxis is TMP-SMX (Bactrim, Septra).

- A. True
 - B. False
-